Savara Inc Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- Savara Inc share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2026-06-30 was 663.79K shares, a 1400.08% increase year-over-year.
- Savara Inc share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2026-03-31 was 388.55K shares, a 287.59% increase year-over-year.
- Savara Inc share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2025-12-31 was 47.66K shares, a 52.51% increase year-over-year.
- Savara Inc share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2025-09-30 was 0.00 shares, a 100.00% decline year-over-year.
- Savara Inc share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2025 was 192.16K shares, a 58.61% decline from fiscal 2024.
- Savara Inc share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2024 was 464.30K shares, a 81.89% increase from fiscal 2023.
- Savara Inc share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2023 was 255.26K shares, a 10789.80% increase from fiscal 2022.
- Savara Inc share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2022 was 2.34K shares, a 99.74% decline from fiscal 2021.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period 12 month |
|---|---|---|
| 2026-06-30 | 663.79K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | 1.10M shares derived: sum of 4 quarters · filed 2026-08-11 |
| 2026-03-31 | 388.55K shares 10-Q · filed 2026-05-12 | 480.46K shares derived: sum of 4 quarters · filed 2026-05-12 |
| 2025-12-31 | 47.66K shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-13 | 192.16K shares 10-K · filed 2026-03-13 |
| 2025-09-30 | 0.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | 175.75K shares derived: sum of 4 quarters · filed 2025-11-12 |
| 2025-06-30 | 44.25K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-13 | 546.06K shares derived: sum of 4 quarters · filed 2025-08-13 |
| 2025-03-31 | 100.25K shares 10-Q · filed 2025-05-13 | 530.80K shares derived: sum of 4 quarters · filed 2025-05-13 |
| 2024-12-31 | 31.25K shares derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-27 | 464.30K shares 10-K · filed 2025-03-27 |
| 2024-09-30 | 370.31K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | 517.24K shares derived: sum of 4 quarters · filed 2024-11-12 |
| 2024-06-30 | 28.99K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-12 | 216.49K shares derived: sum of 4 quarters · filed 2024-08-12 |
| 2024-03-31 | 33.75K shares 10-Q · filed 2024-05-09 | 271.88K shares derived: sum of 4 quarters · filed 2024-05-09 |
| 2023-12-31 | 84.19K shares derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-07 | 255.26K shares 10-K · filed 2024-03-07 |
| 2023-09-30 | 69.56K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | 173.41K shares derived: sum of 4 quarters · filed 2023-11-09 |
| 2023-06-30 | 84.38K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-10 | 103.85K shares derived: sum of 4 quarters · filed 2023-08-10 |
| 2023-03-31 | 17.13K shares 10-Q · filed 2023-05-15 | 19.47K shares derived: sum of 4 quarters · filed 2023-05-15 |
| 2022-12-31 | 2.34K shares derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-30 | 2.34K shares 10-K · filed 2023-03-30 |
| 2022-09-30 | 0.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-10 | 1.90K shares derived: sum of 4 quarters · filed 2022-11-10 |
| 2022-06-30 | 0.00 shares derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-11 | 183.27K shares derived: sum of 4 quarters · filed 2022-08-11 |
| 2022-03-31 | 0.00 shares 10-Q · filed 2022-05-11 | |
| 2021-12-31 | 1.90K shares derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-30 | 889.18K shares 10-K · filed 2022-03-30 |
| 2021-09-30 | 181.37K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-12 | |
| 2020-09-30 | 0.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-12 | |
| 2013-06-30 | 0.00 shares 10-Q · filed 2013-08-05 | 3.66K shares derived: sum of 4 quarters · filed 2013-08-05 |
| 2013-03-31 | 0.00 shares 10-Q · filed 2013-05-15 | 3.66K shares derived: sum of 4 quarters · filed 2013-08-05 |
| 2012-12-31 | 3.66K shares derived: 10-K 12 month − 10-Q 9 month · filed 2013-03-19 | 3.66K shares 10-K · filed 2013-03-19 |
| 2012-09-30 | 0.00 shares 10-Q · filed 2012-11-05 | |
| 2012-06-30 | 0.00 shares 10-Q · filed 2013-08-05 | |
| 2012-03-31 | 0.00 shares 10-Q · filed 2013-05-15 | |
| 2011-09-30 | 0.00 shares 10-Q · filed 2012-11-05 | |
| 2011-06-30 | 0.00 shares 10-Q · filed 2012-08-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| MANNKIND CORP (MNKD) | United States | $1.058B | -30.41 |
| Alto Neuroscience, Inc. (ANRO) | United States | $1.065B | -11.02 |
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| Corvus Pharmaceuticals, Inc. (CRVS) | United States | $0.994B | -23.25 |
| Amphastar Pharmaceuticals, Inc. (AMPH) | United States | $1.116B | 10.93 |
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 | |
| Seaport Therapeutics, Inc. (SPTX) | United States | $1.131B |